Literature DB >> 28864837

Near-infrared spectroscopy (NIRS) and vagus somatosensory evoked potentials (VSEP) in the early diagnosis of Alzheimer's disease: rationale, design, methods, and first baseline data of the Vogel study.

Thomas Polak1, Martin J Herrmann2, Laura D Müller2, Julia B M Zeller2, Andrea Katzorke2, Matthias Fischer2, Fabian Spielmann2, Erik Weinmann2, Leif Hommers2,3,4, Martin Lauer2, Andreas J Fallgatter5,6, Jürgen Deckert2.   

Abstract

Functional near-infrared spectroscopy (fNIRS) and vagus somatosensory evoked potentials (VSEP) show deviant patterns in subjects with Alzheimer's disease (AD) compared to healthy controls. We now aimed at testing the predictive value of these methods in the early diagnosis of AD. The Vogel study is a prospective, observational, long-term follow-up study with three time points of investigation within 6 years. Residents of the city of Würzburg born between 1936 and 1941 were recruited. Every participant underwent physical, psychiatric, and laboratory examinations, and performed an intense neuropsychological testing as well as VSEP and NIRS according to the published procedures. 604 subjects were included. Mean age of the participants was 73.9 ± 1.55 years. The most frequent pathological physical and laboratory examination results were observed for blood pressure (62%), body weight (54%), HbA1c (16%), cholesterol (42%), and homocysteine (69%). Comprehensive analysis of cognitive testing showed mild cognitive impairment (MCI) in 12.3% of the patients. Concurrent major depression was found in 6.6% of the patients. We observed a high rate of MCI and somatic comorbidity in our cohort. The high rate of vascular risk factors and depressive symptoms, all of which are known risk factors of AD, is consistent with the notion that there are multiple options to prevent or postpone the onset of AD in a geriatric population like the one of the Vogel studies.

Entities:  

Keywords:  Alzheimer’s disease; Early diagnosis; Evoked potentials; Near-infrared spectroscopy; Predictive value; Vagus nerve

Mesh:

Substances:

Year:  2017        PMID: 28864837     DOI: 10.1007/s00702-017-1781-0

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  159 in total

1.  Task demand modulations of visuospatial processing measured with functional magnetic resonance imaging.

Authors:  Patrizia Vannini; Ove Almkvist; Anders Franck; Tomas Jonsson; Umberto Volpe; Maria Kristoffersen Wiberg; Lars Olof Wahlund; Thomas Dierks
Journal:  Neuroimage       Date:  2004-01       Impact factor: 6.556

2.  Dementia: a problem for our age.

Authors:  Alison Abbott
Journal:  Nature       Date:  2011-07-13       Impact factor: 49.962

Review 3.  Systematic review of the body of evidence for the use of biomarkers in the diagnosis of dementia.

Authors:  Anna H Noel-Storr; Leon Flicker; Craig W Ritchie; Giang Huong Nguyen; Tarun Gupta; Phillip Wood; Josephine Walton; Meera Desai; Danielle Fraser Solomon; Emma Molena; Rosemary Worrall; Anja Hayen; Prateek Choudhary; Emma Ladds; Krista L Lanctôt; Frans R Verhey; Jenny M McCleery; Gillian E Mead; Linda Clare; Mario Fioravanti; Chris Hyde; Sue Marcus; Rupert McShane
Journal:  Alzheimers Dement       Date:  2012-10-27       Impact factor: 21.566

4.  Neural correlates of a standardized version of the trail making test in young and elderly adults: a functional near-infrared spectroscopy study.

Authors:  Laura D Müller; Anne Guhn; Julia B M Zeller; Stefanie C Biehl; Thomas Dresler; Tim Hahn; Andreas J Fallgatter; Thomas Polak; Jürgen Deckert; Martin J Herrmann
Journal:  Neuropsychologia       Date:  2014-02-10       Impact factor: 3.139

5.  Insulin growth factor binding protein 7 is a novel target to treat dementia.

Authors:  Hope Y Agbemenyah; Roberto C Agis-Balboa; Susanne Burkhardt; Ivana Delalle; Andre Fischer
Journal:  Neurobiol Dis       Date:  2013-09-25       Impact factor: 5.996

6.  The Bayer Activities of Daily Living Scale (B-ADL).

Authors:  I Hindmarch; H Lehfeld; P de Jongh; H Erzigkeit
Journal:  Dement Geriatr Cogn Disord       Date:  1998       Impact factor: 2.959

7.  Combination of biomarkers: PET [18F]flutemetamol imaging and structural MRI in dementia and mild cognitive impairment.

Authors:  Lennart Thurfjell; Jyrki Lötjönen; Roger Lundqvist; Juha Koikkalainen; Hilkka Soininen; Gunhild Waldemar; David J Brooks; Rik Vandenberghe
Journal:  Neurodegener Dis       Date:  2012-02-01       Impact factor: 2.977

Review 8.  Exosomes: vesicular carriers for intercellular communication in neurodegenerative disorders.

Authors:  Anja Schneider; Mikael Simons
Journal:  Cell Tissue Res       Date:  2012-05-19       Impact factor: 5.249

9.  Peroxisomal alterations in Alzheimer's disease.

Authors:  Jianqiu Kou; Gabor G Kovacs; Romana Höftberger; Willem Kulik; Alexander Brodde; Sonja Forss-Petter; Selma Hönigschnabl; Andreas Gleiss; Britta Brügger; Ronald Wanders; Wilhelm Just; Herbert Budka; Susanne Jungwirth; Peter Fischer; Johannes Berger
Journal:  Acta Neuropathol       Date:  2011-05-19       Impact factor: 17.088

Review 10.  A systematic review of biomarkers for disease progression in Alzheimer's disease.

Authors:  David J M McGhee; Craig W Ritchie; Paul A Thompson; David E Wright; John P Zajicek; Carl E Counsell
Journal:  PLoS One       Date:  2014-02-18       Impact factor: 3.240

View more
  2 in total

1.  Micronucleus frequency in buccal mucosa cells of patients with neurodegenerative diseases.

Authors:  Hauke Reimann; Helga Stopper; Thomas Polak; Martin Lauer; Martin J Herrmann; Jürgen Deckert; Henning Hintzsche
Journal:  Sci Rep       Date:  2020-12-17       Impact factor: 4.379

2.  Evaluation of different vagus nerve stimulation anatomical targets in the ear by vagus evoked potential responses.

Authors:  Iñaki Garcia de Gurtubay; Pedro Bermejo; Miguel Lopez; Iñaki Larraya; Julian Librero
Journal:  Brain Behav       Date:  2021-09-22       Impact factor: 2.708

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.